Although GCs inhibit cell growth and trigger apoptotic death in malignant lymphocytes, making them the mainstay of therapy for various leukemias and lymphomas, their effects on breast cancer cell proliferation is quite variable and dependent on the status of ERα expression in these cells (6). This evidence concerns the gene ESR1 and breast carcinoma.